Wright State University

CORE Scholar
Browse all Theses and Dissertations

Theses and Dissertations

2009

Novel Neuroprotectants for Sarin plus CBDP Induced Convulsions
Kaushal V. Joshi
Wright State University

Follow this and additional works at: https://corescholar.libraries.wright.edu/etd_all
Part of the Pharmacology, Toxicology and Environmental Health Commons

Repository Citation
Joshi, Kaushal V., "Novel Neuroprotectants for Sarin plus CBDP Induced Convulsions" (2009). Browse all
Theses and Dissertations. 957.
https://corescholar.libraries.wright.edu/etd_all/957

This Thesis is brought to you for free and open access by the Theses and Dissertations at CORE Scholar. It has
been accepted for inclusion in Browse all Theses and Dissertations by an authorized administrator of CORE
Scholar. For more information, please contact library-corescholar@wright.edu.

Novel Neuroprotectants for Sarin plus CBDP induced convulsions

A thesis submitted in partial fulfillment
of the requirements for the degree of
Master of Science

By

Kaushal Joshi
B.Pharm.,Shri B. M. Shah College of Pharmaceutical Education and Research,2006

2009
Wright State University

COPYRIGHT BY
KAUSHAL JOSHI
2009

WRIGHT STATE UNIVERSITY
SCHOOL OF GRADUATE STUDIES
Date: September 18, 2009

I HEREBY RECOMMEND THAT THE THESIS PREPARED UNDER MY
SUPERVISION BY KAUSHAL V. JOSHI ENTITLED “NOVEL
NEUROPROTECTANTS FOR SARIN PLUS CBDP INDUCED CONVULSIONS” BE
ACCEPTED IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE
DEGREE OF MASTER OF SCIENCE.

_______________________
James B. Lucot, Ph.D.
Thesis Director
________________________
Terry Oroszi
Director, Graduate Program
_______________________
Mariana Morris, Ph.D.
Department Chair
Committee on Final Examination

__________________________
James B. Lucot, Ph.D.

__________________________
David R. Cool, Ph.D.

__________________________
Khalid M. Elased, Ph.D.

__________________________
Joseph F. Thomas, Jr., Ph.D.

Dean, School of Graduate Studies

ABSTRACT

Joshi, Kaushal .M.S., Department of Pharmacology and Toxicology, Wright State
University, 2009.
NOVEL NEUROPROTECTANTS FOR SARIN PLUS CBDP INDUCED
CONVULSIONS. 1

Sarin, also known as Sarin (German agent B) is classified as a weapon of mass
destruction. Sarin (O-isopropyl methyl phosphonofluoridate) is a highly toxic nerve
agent originally produced for chemical warfare and has been used in terrorist activities.
Sarin is an extremely potent acetylcholinesterase inhibitor with high specificity and
affinity for the enzyme. High sarin doses causes death due to anoxia resulting from
airway obstruction, weakness of the muscles of respiration, respiratory failure and
convulsions. Current treatments are still not effective at protecting against long term
effects following exposure. A current approach aims to counteract the increased
glutamatergic and cholinergic neurotransmission occurring in sarin neurotoxicity. In
vitro and in vivo, serotonin (5-HT) 1A agonist prevented toxicity from glutamate. We
determined the neuroprotective capabilities of serotonin (5-HT) 1A agonists as novel
pharmacological countermeasures to chemical warfare agents. Rodents have higher
amount of carboxylesterase enzyme and requires higher doses of sarin than other species.
To address this issue we administered 1.5 mg/kg of CBDP (2-/o-cresyl/-4 H-1: 3: 2benzodioxa-phosphorin-2-oxide), which specifically blocks carboxyl esterase and makes
IV

mouse model comparable to that of human exposure. We determined 1mg/kg dose of
serotonin (5-HT) 1A agonists 8-OH-DPAT from dose response curve based on
neuroprotection, with toxic challenge of 1.5 mg/kg CBDP and dose of sarin yielding 2550 % mortality. This mortality rate gave enough number of survivors with seizures and
neurodegeneration for reliable baselines. Measurements were mortality, weight loss
AChE activity in blood and CNS, functional observational battery (FOB) and histology
compared to control and toxic challenge mice. In addition, a time response curve after
toxic challenge was determined with 1mg/kg of 8-OH-DPAT at time points of 1, 15, 30,
45, 60 minutes and 2, 4, 6 hours. We observed neuroprotection by 8-OH-DPAT in the
dentate gyrus of the hippocampus when administered up to two hours after Sarin. The
ability of the combination of serotonin (5-HT) 1A agonist’s dose and time after toxic
challenge was tested for its ability to reinstate fear potentiated startle (FPS) response.
However this test was invalidated by the response of the control group. DPAT like drugs
could be useful in treatment of long term effects produced by sarin induced convulsions.

V
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Introduction
Organophosphate nerve agents and its history
The organophosphate (OPs) nerve agents are one of the most toxic chemical warfare
agents developed in the 20th century. The first nerve warfare agents were produced by
Nazi Germany during World War II. The first was tabun (GA-German agent A) and
second was sarin (Sarin-German agent B) known as G-type agents. These nerve agents
were weaponized and stocked by Germany, but there have been some debates over use of
these weapons in World War II. The first confirmed use of nerve agents in warfare was
Iraq’s use of tabun and sarin against Iran during the Gulf War(1980-1988). The United
Nations delegation confirmed the use of nerve agents and other chemical warfare agents
which caused at least 45,000 Iranian casualties.(Newmark, 2004) During the Gulf War
(GW-1991), a munitions dump at Khamisiyah, Iraq, was destroyed. Later, in 1996, it was
found that the dump might have contained the organophosphate chemical warfare agents,
sarin and cyclosarin. (Proctor, et al., 2006) The most recent and significant deliberate use
of sarin as nerve agent was two terrorist attacks in Japan. The first nerve gas terrorism
occurred at midnight on 27 June, 1994 in quiet residential area of Matsumoto. About 600
people including residents and rescue staff were exposed to sarin gas. Fifty-eight victims
were admitted to hospitals and seven died. The second attack was on 20th March 1995 in
Tokyo subway during rush –hour., that killed 12 people, 50 severely injured and 5000
people with minor injuries.(Okudera, 2002;Yanagisawa, et al., 2006;Hoffman, et al.,
2007)

The possibility of terrorists using chemical warfare agents (CWA), particularly

sarin is quite real. Nerve agents are well within the capabilities of a good organic
chemist who has access to the necessary raw materials and equipment. The nerve agents’
1

formula and synthetic methods are relatively easily obtained from public information
sources, including the internet. For example, Iraqi military scientists used a U.S. patent
that was declassified in 1975 to make VX (potent chemical warfare nerve agent). The
most popular example is terrorist group Aum-shinrikyo using sarin. (Leikin, et al., 2002)
Sarin is colorless, odorless and most volatile of all the nerve agents; it makes sarin most
likely to be used in terrorist attack.

Sarin and its properties
Sarin is an organophosphorus compound that contains both carbon and phosphorus
atoms. Sarin is basically a derivative of phosphonic (H3PO3) acid. The biological action
of sarin compounds is related to its phosphorylating abilities. (bou-Donia, 2003b)

Figure 1. Chemical structure of sarin (C4H10FO2P). It is also known as isopropyl
methylphosphonofluoridate; isopropoxymethylphosphoryl fluoride and Sarin.

Sarin is chemically similar to organophosphate pesticides and all exert their main
biological effects by inhibiting acetylcholinesterase. G-type agents (GA, Sarin, and GD)
are clear, colorless, and tasteless liquids that are miscible in water and most organic
solvents. Nerve agent vapors are heavier than air and odorless. Sarin is the most volatile
nerve agent, evaporating at about the same rate as water.
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Table 1. Comparison of Physical Properties of Nerve Agents

(Agency for Toxic Substances and Disease Registry., 2003c)

Property

Tabun (GA)

Sarin (Sarin)

Description

Clear, colorless Clear, colorless,
and tasteless
tasteless and
liquid
odorless liquid

Molecular
Weight

162.3 daltons

140.1 daltons

Flash point

172.4 °F
(78°C)
9.8 g/100 g at
77 °F(25°C)

Nonflammable

490 mg/m3 at
77 °F (25°C)

22,000 mg/m3
at 77 °F (25°C)

Solubility in
water
Volatility

Miscible

Soman (GD)

VX

Pure liquid is
Clear, colorless,
tasteless and
odorless liquid,
discolors with
aging to dark
brown
182.2 daltons

Ambered colored,
tasteless and
odorless oily
liquid

267.4 daltons

249.8°F
318.2°F (159°C)
(121°C)
2.1 g/100g at 68 3 g/100 g
°F (20°C)
(miscible below
48.9 °F (9.4 °C))
3,900 mg/m3 at 10.5 mg/m3 at 77
77 °F(25°C)
°F (25°C)

Mechanism of cholinesterase inhibition
After exposure, sarin is primarily absorbed from the respiratory tract. Vapors are
absorbed through the skin at very high concentrations for G agents and at low
concentrations of V agents. The nature and timing of symptoms following dermal contact
with liquid nerve agents depend on exposure dose; effects may be delayed for several
hours. (Agency for Toxic Substances and Disease Registry., 2003b) Sarin causes
neurotoxicity by inhibiting acetylcholinesterase (AChE). AChE is required for
degradation of acetylcholine (ACh). ACh is released in response to nerve stimulation and
binds to post-synaptic acetylcholine receptors. Its action is rapidly terminated by
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hydrolysis with AChE via the serine hydroxyl in the catalytic triad of AChE. AChE very
quickly hydrolyzes ACh, which is a continuous process. Sarin inhibits AChE by
phosphorylating the serine hydroxyl group at the catalytic triad site. The phosphonic acid
ester formed with the enzyme is extremely stable and is hydrolyzed very slowly. The
neurotransmitter ACh continues to elicit a response from the post-synaptic nerve, causing
acute and chronic toxic effects. (bou-Donia, 2003a;Hoskins, et al., 1986;Wang, et al.,
2008)

Figure 2. The 3-dimensional structure of AChE
It has an active center located at the base of a narrow gorge about 20 Å in depth. The
active center includes the following sites (a) the catalytic triad: Glu 334, His 447, and Ser
203; (b) an acyl pocket Phe 295 and Phe 297; (c) a choline subunit: Trp 86,Glu 202, and
Tyr 337; and (d) a peripheral site: Trp 286,Tyr 72, Tyr 124, and Asp 74.

4

Organophosphorus esters inhibit AChE by phosphorylating the serine hydroxyl
group at the catalytic triad site. Phosphorylated AChE undergoes aging—a process that
involves the loss of an alkyl group, resulting in a negatively charged monoalkyl enzyme.

Sarin effects and excitotoxicity
Sarin causes rhinorrhea and tightness in the throat or chest within seconds to minutes
after exposure. (Agency for Toxic Substances and Disease Registry., 2003a) Sarin
causes death due to anoxia, weakness of the muscles of respiration, convulsions and
respiratory failure. The main clinical symptoms of acute toxicity by sarin are seizures,
tremors and hypothermia. (bu-Qare and bou-Donia, 2002) A study conducted on GW
veterans concludes that, sarin and cyclosarin exposure in Iraq was significantly associated
with less proficient neurobehavioral functioning on tasks involving fine psychomotor
dexterity and visuospatial abilities 4–5 years after exposure. The study also suggested a
dose–response association between low-level exposure to sarin and cyclosarin and
specific functional central nervous system effects 4–5 years after exposure. (Proctor, et
al., 2006) Convulsions are a major sign of OP poisoning of the CNS and OP-induced
seizures rapidly leads to structural brain damage. Convulsant doses of soman produce
neuropathology in rats and guinea pigs. Understanding the mechanisms underlying the
pathophysiology of OP-induced neurotoxicity is a crucial step for the development of
effective pharmacological antidotes for long-term effects. (Lemercier, et al., 1983;Filliat,
et al., 1999;Taysse, et al., 2006) The regions of the brain where neuronal damage is
mostly observed are amygdala, piriform cortex, hippocampus and caudate.
Neurodegeneration in the amygdala region of the brain is involved in seizures. (Filliat, et
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al., 1999;Lallement, et al., 1991b) Neuropathology is observed within 20-40 minutes
after convulsion and leads to irreversible neuronal damage leading to long-term effects.
A correlation has been observed between glutamate release in CA1 and CA3 regions of
hippocampus and soman induced seizures(Lallement, et al., 1991b;Lallement, et al.,
1991a;Miller, 2005).

Sarin exposure leads to a series of events. It causes AChE inhibition and
muscarinic receptor over stimulation, which leads to neuronal hyper- excitation and
glutamate overflow. Excessive presynaptic release of glutamate causes activation of
NMDA postsynaptic receptors, which leads to neurodegeneration through excitotoxicity.
Thus, antagonism of the excitotoxic mechanisms may protect the brain from the
deleterious effects of OP nerve agents. Ketamine is a noncompetitive NMDA receptor
ion-channel blocker with neuroprotective and anti-epileptic properties, used for general
anesthesia. It is also. However, it has shown high incidence of psychomimetic side
effects. The antitussive drug dextromethorphan and its active metabolite dextrorphan are
potent NMDA receptor antagonists. Both compounds were shown to possess antiexcitotoxic and anti-epileptic properties, but individuals seeking its dissociative effects
often abuse dextromethorphan. (Miller, 2005) Several other NMDA receptor antagonists
have been shown to exert anticonvulsant effects against nerve agent-induced seizures
when administered as a pretreatment or as post treatment. This antiepileptic feature of
the NMDA receptor antagonists is fully expressed when they are administered
concurrently with muscarinic receptor antagonists. Thus, NMDA receptor antagonists do
not modify the events responsible for the early phase of the seizure, but block the
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subsequent recruitment of glutamate receptor activation and hence the maintenance of
seizure activity. It is important to note that NMDA receptor antagonists may have lethal
interactive effects on respiratory function in soman-intoxicated subjects in the absence of
muscarinic receptor antagonists. Therefore, there is need for other alternatives for
treatment of long-term effects. (Solberg and Belkin, 1997)

Fear potentiated startle (FPS) response
There is a correlation between neuropathology and memory impairments in Soman
treated rats. (Filliat, et al., 1999)

Tokyo subway victims underwent the chronic decline

of memory function after poisoning. (Nishiwaki, et al., 2001) Pavlovian fear
conditioning procedures are used to assess the behavioral, physiological, genetic and
molecular correlates of learning and memory. In the Pavlovian conditioned fear
procedure, a neutral stimulus such as tone is paired with foot shock. After few of these
pairings the tone conditioned stimulus (CS) elicits a variety of behaviors, one of which is
learned fear. One of the prominent of these behaviors is fear-potentiated startle effect, in
which conditioned fear is defined as elevated startle amplitude in the presence versus the
absence of CS. Fear potentiated startle can be measured after a single CS and shock
pairing and can be retained over very long training to test intervals, making it ideal for
examining long-term memory. (Falls and W, 1994;McNish, et al., 1997)

Serotonin (5-HT) 1A agonists as novel treatments
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Serotonin (5-hydroxytryptamine, 5-HT) is a neurotransmitter and utilized in a wide
variety of physiological, sensorimotor and behavioral functions. Serotonin signaling is
mediated by 14 receptor subtypes with different properties. The 5-HT1A subtype is one
of the main mediators of the action of 5-HT which regulates the activity of 5-HT neurons
via auto receptors and it regulates the function of several neurotransmitter systems via
postsynaptic receptors.(Ogren, et al., 2008) 5-HT1A receptors are required for
maintaining normal hippocampal functions. A study of 5-HT1A receptor knockout mice
suggests a role for 5-HT1A receptors in hippocampal-related symptoms such as learning
and memory. (Sarnyai, et al., 2000) Serotonin1A (5-HT1A) receptors are also localized
in the frontal and parietal neocortex, olfactory bulb, cerebral cortex, thalamic and
hypothalamic nuclei, raphe nuclei, septum, hippocampus, several nuclei of the brainstem
Among these the hippocampus and cortex are susceptible to excitotoxic injury.(Nyakas,
et al., 1997;Pompeiano, et al., 1992)
The 5-HT1A receptor agonist repinotan is neuroprotective and attenuates
spatial learning deficits following controlled cortical impact injury. This treatment
strategy may be beneficial in memory impairments in humans following traumatic brain
injury due to exposure to sarin. (Kline, et al., 2001;van der Staay, et al., 2008) The
neuroprotection is result of attenuation of the activity of both N-type Ca2+ channels and
N-methyl-D-aspartic acid receptors and MAPK-mediated inhibition of a caspase 3-like
enzyme pathway. (Adayev, et al., 1999;Harkany, et al., 2001;van der Staay, et al., 2008)
Another full agonist, 8-OH-DPAT shows neurological protection after
traumatic brain injury (TBI). The mechanism for the protective effects of 8-OH-DPAT
after TBI is still not clear. (Kline, et al., 2004) 5-HT1A receptor agonist 8-OH-DPAT
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has inhibited neuronal cell death in vivo and in vitro. (Adayev, et al., 1999;Oosterink, et
al., 2003) The OPs nerve agent exposure causes seizures that induce release of
glutamate. Glutamate causes excitotoxicity and leads to neurotoxicity. One of the
hypothesized mechanisms is inhibition of glutamate release by activation of 5-HT1A
receptors. (McDonough, Jr. and Shih, 1993;Srkalovic, et al., 1994) Additionally,
several full and partial 5-HT1A receptor agonists have been developed, generally with
lower selectivity than 8-OH-DPAT. A current approach aims to counteract the increased
glutamatergic and cholinergic neurotransmission occurring in sarin neurotoxicity. The
physiological mechanisms underlying the neuromodulatory functions of 5-HT1A
receptors are presently not well characterized. We tested 8-OH-DPAT as a
neuroprotectant against sarin poisoning. (Ogren, et al., 2008)

Use of CBDP
Rodents have a high amount of carboxylesterase enzyme compared to humans.
Carboxylesterase is a chemical scavenger that inactivates organophosphate nerve agents
among other things. This makes rodents relatively insensitive to the toxic effects of
organophosphorus compounds. There will be differences in the neurotoxicity produced
by single dose of sarin in rodents in comparison to humans. So we propose to use CBDP
(2-/o-cresyl/4H: 1: 3: 2-benzodioxaphosphorin-2-oxide) which is a carboxylesterase
inhibitor. Subcutaneous CBDP has reduced LD 50 range of soman across species from
22.8 to 125 µg/kg to 11.8 to 15.6 µg/kg. (Clement and Erhardt, 1990;Maxwell, et al.,
1987) Doses of CBDP between 1.0 to 2.0mg/kg should prove useful as pretreatment in
OPs induced neurotoxicity in rat, it makes mouse model comparable to actual human
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exposure. (Jimmerson, et al., 1989) Preliminary work has shown that an optimum dose
of 1.5 mg/kg CBDP specifically blocks carboxylesterase, and potentiates the response of
C57BL/6 mice to sarin. This dose of CBDP does not inhibit AChE and produce toxic
effects of its own.

Hypothesis
We tested the hypothesis that the 5-HT1A agonist 8-OH-DPAT (8-hydroxy-2-(di-npropylamino) tetralin) will work as a neuroprotectant against sarin poisoning. The toxic
challenge (TC) was the dose of sarin with CBDP yielding 25-50% mortality in the group.
That gave enough number of survivors with seizure and neurodegeneration for reliable
baselines. We determined the neuroprotective dose response curve for 8-OH-DPAT
against the toxic challenge. Then, we determined time response curve of the best dose of
5-HT1A agonist based on neuroprotection. Finally, we tested the correlary hypothesis
that a selected dose will prevent from memory deficits.

Specific Aim 1
Test the hypothesis that best dose of 8-OH-DPAT can act as a neuroprotectant for
neurotoxicity produced by sarin induced convulsions in a dose dependant manner.
Measurements were mortality, weight loss and FOB compared to control and toxic
challenge mice. This was used to select best dose for subsequent studies.

Specific Aim 2
10

Test the hypothesis that best dose of 8-OH-DPAT can act as a neuroprotectant for
neurotoxicity produced by sarin induced convulsions in a time dependant manner.
Measurement were mortality, weight loss, FOB, ChE activity and histology compared to
control and toxic challenge mice

Specific Aim 3
The ability of the combination of 8-OH-DPAT agonist dose of best dose and selected
time after toxic challenge was tested for its ability to reinstate Fear potentiated startle
(FPS) response.

11

Research design

Animals
The subjects were C57BL/6 male mice at 20-25 g body weight. They were housed in an
AAALAC (Association for the Assessment and Accreditation of Laboratory Animal care)
approved facility on a 12hr light/dark cycle with free access to food and water. All of our
previous studies have been with this strain. Before administration of drugs animals were
kept 1 week in house cage so they could acclimate to the environment and handled for 3
days to eliminate signs of stress. Studies in mice have demonstrated interstrain
differences both in neurochemical measures and in cognitive abilities. A C57BL/6J
mouse has good learning abilities and memory trace retention (at 10 days) in a simplified
Morris maze. (Bel'nik, et al., 2009)

Drugs
We used diluted sarin (Aberdeen Proving Ground, MD) from the stock of 1.9 mg/ml
saline solution. It was injected in a volume of 1 ml/200g weight for each dose. Mice
received 0.5ml/a00g body weight, for a dose of 1.5 mg/kg CBDP (a generous gift of R.A.
Donald M.Maxwell, Pharmacology Division, United States Army Medical Institute of
Chemical Defense, Aberdeen Proving Ground, Maryland 21010-5425, USA). We diluted
CBDP to 0.3mg/ml in a 10% ethanol and propylene glycol solution for the dose of
1.5mg/kg.

Sarin and CBDP injections are subcutaneous. Our previous work established

1.5mg/kg CBDP as the optimum dose for carboxylesterase inhibition and it does not
interfere with cholinesterase activity. Sarin was injected 1 hour after CBDP injection to
12

allow inhibition of carboxylesterase. 8-OH-DPAT doses of 0.3,1, 1.7 and 3 mg/ml were
selected for dose response curve. 8-OH-DPAT was dissolved and diluted in saline for
volume of 1ml/200g weight for each dose. Doses of 8-OH-DPAT were given 1 minute
after Sarin injection for dose response curve. For the time response curve best selected
dose (1 mg/kg) was given at different time points 1,15,30,45,60 min and 2,4,6 hours after
toxic challenge.

Weight Loss
There was observed correlation between organophosphate nerve agent produced
neurotoxicity and weight loss in mice. (Filliat, et al., 2007) In our previous work, we
observed that toxic challenge dose causes weight loss in mice. We measured percentage
body weight loss of mice on the first and third day after the injections.

Functional Observational Battery (FOB)
FOB contains end points that provides information of general health of mice. It also
provides data needed for analysis of neurotoxicity produced by neurotoxicants. (Ross J F,
2000) We used a modified FOB which was used for ChE inhibitor pesticides.(Moser,
1995;Shih and Romano, 1988) Mice were observed for a Functional Observational
Battery for 1-hour post Sarin dosing. The FOB scores were taken 15, 30, 45 and 60 min
after the sarin dose. The FOB is based on 5 criteria with a total low score of 6 and a high
score of 21. It includes measures of posture, motor behavior, gait, breathing and eye
closure. Data is presented as percent of maximum score.

Table 2. Functional observation battery scoring
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 normal

 flattened

prostration

 side/contorted

Motor
behavior

 normal

 tail twitching

 tremors

 convulsions

Gait score

normal

 severe
staggering

 unable to move

 severe protrusion

Posture

 hypo-loco
 staggering
 splayed

Eyelid

open

 half closed

 slight
protrusion

Breathing

 normal

 fast shallow

 slow labored

Blood and brain cholinesterase (ChE) activity
We used modified version of the colorimetric assay of acetyl cholinesterase on Packard
FusionTM Microplate Analyzer. (ELLMAN, et al., 1961) The mice were decapitated
after 14 days of Sarin injection and blood were collected in heparin tubes. Two eppendorf
tubes were prepared for each blood sample inhibited for inhibition of butrylcholinesterase
(BChE) activity and uninhibited for total cholinesterase activity. For inhibited tubes 5ul
10mM iso-OMPA (tetraisoproppyl-pyrophosphoramide) and for uninhibited 5ul of
NaPO4 pH 7.4 are incubated for 45 minutes on ice. That allows for inhibition of BChE
activity in inhibited tubes. Following incubation 245 µl 0.1 M NaPO4 pH 7.4 buffers is
added in inhibited and uninhibited tubes and mixed by inverting tubes. Than 96 well plate
is used with triplicate sample. Total 6 wells are used for each sample, with 140 µl 0.1 M
NaPO4 pH 8.0, 20ul sample, 20 µl 10 mM DTNB (Dithionitrobenzoate) and 20µl 10mM
ATCh (Acetyl choline). The plate was transferred to the plate analyser as quickly as
14

possible. BChE activity is then calculated by subtracting AChE activity from total ChE
activity. Brain cholinesterase activity determined as described above. Brain samples are
sonicated in 0.1 M NaPO4 pH 7.4 buffer containing 0.5 % Tween 20 with a probe
sonicator for 5 seconds for 2-3 times. We used Tween 20 rather than Triton X-100,
which inhibits BChE activity. (Li, et al., 2000) Samples were centrifuged at 13000 rpm
for 5 minutes at 4ºC. For inhibited sample, 1µl of iso-OMPA is added to 99µl sample
supernatant. Protein content of the supernatant was determined using Bradford method
(BioRad, Inc)

Neuropathology
Fourteen days post sarin treatment, mice were lightly anesthetized with CO2 ,and
sacrificed by decapitation and brain tissue collected for histology. Brains were quickly
removed and quickly frozen into isopentane for 10-12 seconds and then stored at -80°C
until sectioning. Frozen coronal sections of 10 µm were collected using cryostat (Thermo
Shandon series, Pittsburg, PA) and TFM (TBS, INC., Durham, NC) as freezing medium).
The section were collected on Fisher plus slides and stored in -20°C until fixed for
staining. We performed immunohistochemistry using Glial fibrillary acidic protein
(GFAP) as a marker for neurodegeneration. GFAP is a intermediate filament (IF) protein
that is found in astrocytes in CNS. There is correlation between neurodegeneration and
improper GFAP regulation. Neurodegenerative condition leads to higher expression of
GFAP that leads to glial scarring. (Liedtke, et al., 1996) On the first day of staining, the
slides were taken out and let dry about 30 minutes at room temperature. A boundary was
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made around sections with a liquid repellent PAP pen (Daido Sangyo, Tokyo, Japan) and
let dry about 10-15 min. Then slides were transferred to a humid chamber which is large
petri dish with filtered paper saturated with distill water in a plastic box covered with lid
on top. The slides were washed with 3 times for 5 minutes and 1 time for 10 minutes
with 0.01 M phosphate buffer solution containing 0.1 % triton (0.01 M PBS/0.1 %TX).
The last wash was rinsed and allowed to dry. The slides were blocked with 10 % normal
horse serum (10 % NHS is made by using 500µl normal horse serum in 4.5 ml of 20 mM
TBS (Tris buffered saline) for 30 minutes. Drain off NHS and allow PAP ring to dry.
Primary antibody solution was prepared at 1:150 dilution of rabbit anti-GFAP (Zymed,
South San Francisco, CA) in 0.01 M PBS/0.1 %TX to block antibody. The slides were
kept overnight at room temperature. Next day primary antibody was drained off from the
slides. Then the slides were washed with 3 times for 5 minutes and 1 time for 10 minutes
with 0.01 M PBS/0.1 %TX. Following this step, all steps were performed in the dark.
Fluorescent probe-conjugated secondary antibody solution horse anti-rabbit FITC
(Amersham, Pittsburg, PA) at a 1:50 dilution in 0.01 M PBS/0.1 % TX were prepared
and added to slides which are kept for 2-4 hours. Then the slides were washed with 3
times for 5 minutes and 1 time for 10 minutes with 0.01 M PBS. We allowed slides to
dry and coverslip with gel –mounting medium (Bio-meda, Foster city, CA). Slides were
stored at 4°C. We examined slides using a Leicia microscope fitted with an Optronics
camera. Total cell count was done specified area. Images will be analyzed using ImageJ
(1.41O) software.

Procedure for FPS testing
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FPS consists of pre-training, training and post training sessions. Mice are tested in
SM100 startle monitor system version 6.12. (Kinder Scientific, 2001, Poway, CA) In the
fear-potentiated startle procedure, conditioned fear is operationally defined as elevated
startle amplitude in the presence versus absence of the stimulus that was previously
paired with shock. This assumes that the CS does not increase or decrease startle
amplitude prior to Pavlovian fear conditioning. If it does then these unconditioned
effects on startle could exaggerate or mask subsequent conditioned fear. For these reason
the FPS test is administered prior to Pavlovian fear conditioning and is referred to as the
pre-test. After a 5 min acclimation period, they are presented with 32 startle stimuli at
two white noise intensities in 50ms pulses at 75 & 80 db ( 8 of each), both in the
presence and absence of the 30 sec, 12kHz pure tone of 70dB CS. The inter interval
between trial is 1 min. The training session (Pavlovian fear conditioning) consists of 5
min. acclimation, 20 tone (CS of 29.5 sec, 12 kHz pure tone of 70dB) and 0.5 sec of
electric shock of 0.4 mA. Pavlovian fear conditioning is repeated for two days for total
of 40 trials. The inter interval between trial ranges from 1 min to 3.5 min. The posttraining test is same as pre training test and is conducted 24 hour after Pavlovian fear
conditioning. Finally, the percent fear-potentiated startle is computed by dividing the
difference score by the amplitude of startle on noise burst alone trails and multiplying by
100 (FPS= [(tone + noise burst alone- noise burst alone)/ noise burst alone] X100. (Falls,
2002)

Statistical analysis
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We used using Statistica software (version 7) for statistical analysis. One-way ANOVA
was used to test for differences among two or more independent groups. Fisher Least
significant difference test was used to identify individual group differences. In all groups
*=p<0.05, significant, different from toxic challenge.
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Results

Mortality rates from dose response curve for 8-OH-DPAT after TC
We measured the mortality rate in different groups to find if there is any effects of
DPAT on mortality. The lower dose DPAT group showed lower mortality rate. The
highest dose of DPAT (3 mg/kg) increased the lethality of the TC (Table 3).
Dose

N

deaths

Percent

TC

9

3

33.33%

0.3mg/kg

8

2

25.00%

1mg/kg

12

3

25.00%

1.7mg/kg

9

4

44.44%

3mg/kg

6

5

83.33%

Table 3 Mortality rates comparison of different doses of 8-OH-DPAT given 1 min. after
toxic challenge (TC). TC was 1.5 mg/kg of CBDP and 32 µg/kg dose of sarin.

Weight loss from dose response curve for 8-OH-DPAT after TC
To find out correlation of neurotoxicity and weigh loss we measured weight loss up
to 3 days post sarin injections. Mean percentage weight loss at day1 and day3 after
injection, comparison of different doses of 8-OH-DPAT given 1 minute. after toxic
challenge (TC) was measured. TC was 1.5 mg/kg of CBDP and 32 µg/kg dose of sarin.
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At day 1, there was greater weight loss in 0.3 and 1.7 mg/kg dose of 8-OH-DPAT group
compared to TC group. The weight loss of 1 mg/kg dose group was lower than TC
group. (F3, 27 =7.2907, p<0.05) A one way ANOVA showed significant difference of
weight loss of 0.3 and 1.7 mg/kg dose of 8-OH-DPAT group compared to TC group. At
day 3, there was no significant difference in the weight loss of any of the group, but 1
mg/kg dose group did not lose weight as much as TC group. The two doses 0.3 and 1.7
mg/kg showed almost similar weight loss compared to toxic challenge. Based on weight
loss and mortality rates we selected 1mg/kg dose for subsequent studies. (Figure. 3)

-14

weigh loss from dose response of 8-OH
DPAT

% weight loss

-12
-10
-8

*
-6

*

mean @ day 1
mean @ day 3

-4
-2
0

TC

0.3mg/kg 1mg/kg 1.7mg/kg

Figure. 3 mean percentage weight loss on day 1 and 3 of of different doses of DPAT
groups compared to toxic challenge group.

Mortality rates from time response curve for 8-OH-DPAT
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The mortality rate of the 1 mg/kg DPAT group was lower than toxic challenge. The
weight loss at day 1 and 3 was also lower than TC group. Based on these results we
chose 1mg/kg dose of DPAT for time response curve. The mortality rate of 1, 15 and 30
min 8-OH-DPAT group is not higher than TC group, but 45 and 60 min 8-OHDPATgroup is higher than TC group. (Table 4) The 2 hour and 4 hour DPAT groups’
toxic challenge was 1.5mg/kg of CBDP and 1 hour later 40ug/kg dose of sarin. The 4
hour DPAT group mortality rate was higher than toxic challenge group. (Table 5) The 6
DPAT group toxic challenges were 1.5mg/kg of CBDP and 1 hour later 42ug/kg of sarin.
The 6 hour DPAT group mortality rate was higher than toxic challenge group. DPAT did
not have any effects on mortality rates as some of the mice died before DPAT injections.
(Table 6)

Dose

N

deaths

Percent

TC

9

3

33.33%

1 min DPAT

12

3

25.00%

15 min DPAT

10

2

20.00%

30 min DPAT

6

2

33.33%

45 min DPAT

8

3

37.50%

60 min DPAT

12

7

58.33%

Table 4. Mortality rates of 1 mg/kg DPAT at various time points post toxic challenge
(TC) injections compared to TC.
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Dose

N

deaths

Percent

TC

6

2

33.33%

2hr DPAT

9

3

33.33%

4hr DPAT

10

6

60.00%

Table 5. Mortality rates of 2 and 4 hour DPAT groups post toxic challenge (TC)
injections compared to TC.

Dose

N

deaths

Percent

TC

5

2

40.00%

6hr DPAT

11

5

45.45%

Table 6. Mortality rates of 6 hour DPAT group post toxic challenge (TC) injections
compared to TC

Weight loss from time response curve for 8-OH-DPAT
Mean percentage weight loss at day1 and day 3 comparisons of vehicle control,
DPAT control, toxic challenge (TC) and 1mg/kg of 8-OH-DPAT given after TC at
different time points was performed. The control group received propylene glycol and
1-hour later saline. DPAT control group received 1 mg/kg dose of 8-OH-DPAT. At day
1, there was higher weight loss in 8-OH-DPAT group of 15, 30, 45 and 60 min than toxic
challenge group. There was lower weight loss in 1 min 8-OH-DPAT group. There was
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no significant difference of weight loss between TC and 8-OH-DPAT group at different
time points at day 1. One-way ANOVA showed significant difference between control
group and TC, 15, 30, 45, 60-minute 8-OH-DPAT group. (F7, 53=6.2234, p<0.0001) At
day 3, there was higher weight loss in 60 min 8-OH-DPAT group than toxic challenge
group. At day 3, there was lower weight loss in 8-OH-DPAT group 1, 15, 30 and 45 min
compared to TC group. There was no significant difference between of weight loss
between TC and 8-OH-DPAT group at different time points at day 3. One way ANOVA
showed significant difference between control group and TC, 15, 45, 60 minute 8-OHDPAT group. (F7, 51=5.2500, p<0.001) (Figure 4) There is higher weight loss on day 1
and 3 of 2 hour DPAT group compared to toxic challenge. (Figure 5) There is lower
weight loss in 6 hour DPAT group compared to toxic challenge at both day 1 and 3.
(Figure 6)
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Weight loss

-20
-18
-16

% weight loss

-14
-12
-10
mean @
1
mean @
3

-8
-6
-4
-2

* *

*
*

0
2

Figure 4. Mean percentage weight loss on day 1 and 3 of DPAT group compared to toxic
challenge group.
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weight loss of 2,4 hour DPAT groups
-16.00
-14.00
% weight loss

-12.00
-10.00

day 1

-8.00

day 3

-6.00
-4.00
-2.00
0.00
TC

2 hr. DPAT

4 hr. DPAT

Figure 5. Mean percentage weight loss on day 1 and 3 of 2 and 4 hour DPAT groups
compared to toxic challenge group.

weight loss of 6 hour DPAT group
-25.00

% weight loss

-20.00
-15.00
day 1

-10.00

day 3

-5.00
0.00
TC

6 hr. DPAT

Figure 6. Mean percentage weight loss on day 1 and 3 of 6 4 hour DPAT group compared
to toxic challenge group.
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Functional observational battery scores from time response curve for 8OH-DPAT
All groups injected with Sarin showed signs of poisoning and mortality. This
is required in groups for brain pathology. Functional Observational Battery scores were
calculated for animals injected with the vehicle control, DPAT control, TC and TC+
DPAT at different time points thereafter. A one way ANOVA performed on percentage
of maximum score showed significant differences between control and Sarin treated
groups. (F7, 65=54.520, p<0.0001) (Figure 7) For 2, 4 and 6 hour DPAT groups FOB
scores were measured at longer time points until 24 hours. At 24 hours 2 and 4 hours
FOB scores are lower than toxic challenge group. (Figure 8) FOB score of 6 hour DPAT
group is higher than toxic challenge at 24 hours. (Figure 9)

FOB scores with DPAT
120.0

% FOB

100.0
80.0
60.0
40.0
20.0

*

*

0.0
Vehicle DPAT
control control

TC

1 min
DPAT

15 min 30 min 45 min 60 min
DPAT
DPAT
DPAT
DPAT

Figure 7. Percentage FOB scores of DPAT, vehicle control groups to toxic challenge
group.
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FOB scores of 2,4 hour DPAT group
120

pecentage

100
80

TC

60

2 hr DPAT
4 hr DPAT

40
20
0
FOB 1hr

FOB 2hr

FOB 4hr

FOB 24hr

Figure 8. Mean percentage FOB scores of 2, 4 hour DPAT groups compared to toxic
challenge at different time points.

FOB scores of 6 hour
DPAT group
120

percentage

100
80

TC

60

6 hr DPAT

40
20
0
FOB 1hr

FOB 2hr

FOB 4hr FOB 24hr

Figure 9. Mean percentage FOB scores of 6 DPAT group compared to toxic challenge at
different time points.
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Blood ChE and AChE activity
The blood ChE and AChE activity was measured 14 days post injection. The ChE
activity was measured on trunk blood collected by decapitation. There is no significant
difference of ChE activity between any of the groups. There is also no significant
difference between AChE activities between any of the groups (Figure 10)

Blood ChE and AChE rate
nmole/min/ug protein

1.4
1.2

1.0
0.8
0.6

ChE rate Mean

0.4

AChE rate Mean

0.2

0.0
Vehicle
control

TC

1 min
DPAT

15 min 30 min 60 min
DPAT DPAT DPAT

Figure 10. Blood ChE activity of different groups 14 days post Sarin injection.

Frontal cortex AChE activity
The frontal cortex ChE and AChE activity was measured 14 days after injection.
Mice were euthanized using CO2 and decapitated. The ChE activity in all 8-OH-DPAT
groups after15 min was lower than the toxic challenge group. (Figure 11)
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FC ChE and AChE rate
nmole/min/ug protein

14.0
12.0
10.0

8.0
ChE rate Mean

6.0

AChE rate Mean

4.0
2.0

0.0
TC

1 min
DPAT

15 min
DPAT

30 min
DPAT

45 min
DPAT

60 min
DPAT

Figure 11. Frontal cortex ChE and AChE activity in DPAT groups compared to TC group

GFAP cells counts in dentate gyrus from time response curve for 8-OHDPAT
Glial fibrillary acidic protein (GFAP) is a marker for neurodegeneration, which is
highly responsive to neuronal damage. An increase in GFAP is an indication of trauma
to these cells. GFAP cell counts was conducted in dentate gyrus of hippocampus for
animals injected with the vehicle control, DPAT control, TC and 1 mg/kg DPAT at
various time points post TC injections at 14 days post injection. We observed significant
differences of GFAP cells in dentate gyrus of hippocampus in up to 2 hour time points
compared to TC group, with the values the same as for background. (F7, 37=7.0575,
p<0.0001) (Figure 12, 13)
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fluorescent cells/2.0 x 105 um2

GFAP cells in dentate gyrus 14 days post
injection
*

300.0
250.0
200.0

150.0
100.0
50.0
0.0

Vehicle DPAT GB only 1 min 15 min 30 min 45 min 60 min
control control
DPAT DPAT DPAT DPAT DPAT

Figure 12. GFAP cells in dentate gyrus of hippocampus in different groups .

fluorescent cells/2.0 x 105 um2

GFAP cell counts in 2,4 hour DPAT
140.0
120.0
100.0

*

80.0
60.0
40.0
20.0

0.0
TC

2 hr DPAT

4 hr DPAT

Figure 13. GFAP cells in dentate gyrus of hippocampus in 2 and 4 hour DPAT groups

Images of Dentate Gyrus of Hippocampus of different groups stained
for GFAP
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Below are images of the dentate gyrus of the hippocampus of different groups stained for
GFAP. (Figure 14,15) All the picture were taken on 20x magnification using optronics
camera using a Leica microscope. We euthanized all the groups two weeks after
injections. All the injections were SC. route. The control group received propylene
glycol and 1 hour later saline. The DPAT control group received propylene glycol, 1 hour
later saline and 1 minute after 1 mg/kg of 8-OH-DPAT. The toxic challenge group
received 1.5 mg/kg of CBDP and 1 hour later 32 ug/kg of Sarin injection. The DPAT
groups received toxic callenge and 1mg/kg of 8-OH-DPAT at time points according to
groups.
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Figure 14. Dentate gyrus of hippocampus of different groups ,mouse euthanized 14 days
after injection (a) control group dose with propylene glycol and saline (b) toxic challenge
group dosed with 1.5mg/kg CBDP and 32ug/kg Sarin (c) DPAT control group dosed with
propylene glycol, saline and 1mg/kg 8-OH-DPAT (d) 1 min DPAT group dosed with
toxic challenge and 1 minute later 1m/kg 8-OH-DPAT
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Figure 15 Dentate gyrus of hippocampus of time points of DPAT groups, 1mg/kg DPAT
given after toxic challenge at (a) 15 min (b) 30 min (c) 45 min (d) 60 min
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Fear potentiated startle (FPS) response
We performed fear potentiated startle response test on three groups control,
toxic challenge and 45 min DPAT group.

Mice were assigned into groups according to

averages of their startle amplitude. All injections were S.C. route. The control group
received propylene glycol and 1-hour later saline. The toxic challenge group received 1.5
mg/kg CBDP and 1-hour later 42ug/kg of Sarin. The DPAT group received toxic
challenge and 45 minute later 1mg/kg of 8-OH-DPAT. Three weeks after injections mice
were fear conditioned for Pavlovian fear conditioning the training session which consists
of 5 min. acclimation, 20 tone (CS of 29.5 sec, 12 kHz pure tone of 70dB) and 0.5 sec of
electric shock of 0.4 mA. Pavlovian fear conditioning was repeated for two days for 40
trials. 24 hours later mice were tested for posttest, which is same as pre test. At 75, 80
db white noise and average FPS TC group learned the conditioning. We previously
preformed three weeks FPS studies on asymptomatic doses of Sarin (0.4 LD50) and the
Sarin group did not learn. In our experiment the symptomatic dose of Sarin group
learned and left our test inconclusive.

FPS 75
50.0

% FPS

40.0
30.0
pre test

20.0

post test

10.0
0.0
Control

TC

Tc+45 min DPAT
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Figure 16. Fear potentiated startle at 75 db white noise

% FPS

FPS 80
70.0
60.0
50.0
40.0
30.0
20.0
10.0
0.0
-10.0
-20.0

pre test
post test

Control

TC

Tc+45 min DPAT

Figure 17. Fear potentiated startle at 80 db white noise of different groups.
60.0

average FPS

50.0

% FPS

40.0
30.0

pre test
post test

20.0
10.0
0.0
Control

TC

Tc+45 min DPAT

Figure 18. Average Fear potentiated startle of 75 and 80db white noise of different
groups.

Immunohistochemistry of FPS group
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The FPS control mice were treated with propylene glycol and saline. The TC
group received 1.5mg/kg CBDP and 42ug/kg Sarin. The DPAT group was injected
1.5mg/kg CBDP and 42ug/kg Sarin and 45 minutes later 1 mg/kg of 8-OH-DPAT. Mice
were euthanized 4 weeks after injection. Immunohistochemistry was performed on
frozen sections and GFAP cells in dentate gyrus region were calculated. GFAP cell were
significantly lower in dentate gyrus of hippocampus in control and 45 min DPAT group
compared to TC group. (F2, 24=82.174, p<0.0001) (Figure 19)

fluorescent cells/2.0 x 105 um2

GFAP cells in dentate gyrus 4 week post
injecton
300.0

*

250.0
200.0
150.0
100.0
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control

TC

TC+45 min DPAT

Figure 19. GFAP cells in dentate gyrus of hippocampus in different groups.
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Discussion
The main objective of the study was to look for novel neuroprotectants for
treatment of long-term effects produced by sarin induced convulsions. This required
identification of the dose of sarin that will produce a mortality rate with enough survivors
for reliable baseline. We also wanted to make our model comparable to actual human
exposure. We used CBDP with sarin to inhibit the high levels of carboxylesterase seen in
rodents to reduce the total sarin dose and thus to make the mouse model closer to
humans. We tested the 5-HT-1A agonist 8-OH-DPAT for treatment of sarin and CBDP
induced convulsions. We performed dose response and time response curves for 8-OHDPAT and looked at the parameters of mortality rates, weight loss, FOB, blood and brain
cholinesterase activity, immunohistochemistry for degenerating neurons and FPS. We
observed neuroprotection by DPAT in the dentate gyrus of hippocampus up to 2 hours
after the administration of the toxin. We also tested other 5-HT-1A agonists in our
laboratory but they were ineffective. The mechanism of the neuroprotection produced by
DPAT is still not clear. We observed that 8-OH-DPAT influenced on the pattern,
intensity, and duration of sarin-induced seizures using ECoG; this mechanism could
underlie the neuroprotection produced by 8-OH-DPAT in dentate gyrus of hippocampus.

Use of Sarin and CBDP
Carboxylesterase are important in the detoxification of a number of
organophosphorus insecticides. Humans have low carboxyl esterase in blood and tissue
in comparison of rodents. (Pope, et al., 2005) Rodents will require higher doses of sarin
to produce its effects. Administration of CBDP significantly reduced the dose of sarin
necessary to produce symptoms. Administration of CBDP potentiated Sarin almost five
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times from 200ug/kg to 42ug/kg to produce 25-50 % mortality rates. Carboxylesterase is
important detoxifier of sarin. The administration of this dose of CBDP specifically
blocks CaE; therefore less Sarin dose was required to produce its effects. The CBDP and
Sarin injection were separated by 1 hour. At the time of Sarin administration carboxyl
esterase was blocked by CBDP. The lower dose of Sarin irreversibly blocked
cholinesterase and produced toxic effects.

CBDP administration reduced our Sarin dose

from a range of 160-200 ug/kg to 32- 42 ug/kg., while even repeated low level sarin
exposure of 64 ug/kg is asymptomatic. (Jimmerson, et al., 1989) CBDP dose of 2 mg/kg
or higher significantly lowers cholinesterase activity in blood and brain.(Mach, et al.,
2008) We used 1.5 mg/kg of CBDP which did not interfere with cholinesterase activity,
making our model closer to actual human exposure.

Dose response curve of 8-OH-DPAT
We determined the neuroprotective dose response curve for the 5-HT-1A agonist
8-OH-DPAT against the toxic challenge of 1.5mg/kg of CBDP and 32ug/kg of Sarin over
the range from of 0.3, 1, 1.7 and 3 mg/kg of 8-OH-DPAT. The 5-HT1A receptor is the
most studied and best characterized 5-HT receptor subtype to date. 5-HT1A receptors are
abundantly expressed in cortical and hippocampal (CA1/CA3 and dentate gyrus) regions
that are critically involved in learning and memory and susceptible to neuronal damage.
(Kline, et al., 2007) 5-HT1A receptor involvement in modulation of the major
neurotransmitters ACh, DA, and glutamate, the serotonin (5-HT) system, is considered a
significant pharmacological target for the treatment of various central nervous system
(CNS) diseases. Administration of 5-HT1A receptor agonists before or after focal
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cerebral ischemia provides neuroprotection as evidenced by decreased histopathology.
Single administration 5-HT1A receptor agonist of 8-OH-DPAT decreases cortical lesion
volume and hippocampal neuron survival. Single systemic administration of the 5-HT1A
receptor agonist 8-OH-DPAT enhances behavioral recovery after experimental traumatic
brain injury (TBI). Intraperitoneal administration of 0.5 mg/kg dose of 8-OH-DPAT
confers neurological protection after TBI in Hippocampal CA1/CA3 region. (Cheng, et
al., 2008; Kline, et al., 2004) 8-OH-DPAT is much more potent when injected
subcutaneously than when injected Intraperitoneal, the potency difference being
approximately 17-fold. (Fuller and Snoddy, 1987) The important influence of route of
administration on the potency of 8-OH-DPAT must be considered in interpreting the
various functional effects that have been reported with it. After oral administration, 8OH-DPAT goes first-pass metabolism and shows low oral bioavailability of, rather than
poor absorption from the GI tract. (Mason, et al., 1995) We selected doses of in range of
0.3 to 1.7 mg/kg of 8-OH-DPAT for subcutaneous administration for our dose response
curve. The mortality rate for our toxic challenge group is 33.33 %. The lower dose
group 0.3 and 1 mg/kg of 8-OH-DPAT showed less mortality than toxic challenge but
mortality increased with higher doses of 1.7 and 3 mg/kg. 8-OH-DPAT is not a rescue
drug for treatment of nerve agent exposure therefore; we did not see any significant
effects on mortality rate. The reason for higher mortality rate in higher doses of DPAT
groups is still not clear. There could be unknown interaction between higher doses of
DPAT with CBDP or Sarin causing higher mortality.
We measured total body weight loss on mice up to 3 days post sarin
injections. Body weight is related to general health status, periodic measurement can
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indicate if animals are recovering or still in poor health. Knowledge of body weight is
crucial for neurotoxicity testing. Body weight loss can be an indicator of neurotoxin
effects on CNS. Rats treated with artelinic acid showed signs of neurotoxicity and
significantly lost weight. (Si, et al., 2007) At day, 1 0.3 and 1.7 mg/kg DPAT group
showed higher weight loss compared to toxic challenge group. Only one mouse survived
in 3mg/kg group after injection. We did not include that group in our results due to low
number in the group. At both day 1 and 3, 1 mg/kg the DPAT group weight loss was
lower than the toxic challenge group, while at day 3 other doses had higher weight loss.
We selected as the best dose 1mg/kg of 8-OH-DPAT for the time response curve with
toxic challenge based on lower mortality and lower weight loss data.

Time response of 1 mg/kg of 8-OH-DPAT with toxic challenge
We performed a time response of 8-OH-DPAT with the 1mg/kg selected dose
from the dose response curve. We gave DPAT at 1, 15, 30, 45, 60 minutes 2, 4 and 6
hour after toxic challenge. Weight loss of mice treated with DPAT 1 and 15 min after
toxic challenge was lower than TC group. At later time points in DPAT group the
morality was similar or higher than toxic challenge group. Since DPAT is not a rescue
drug it does not reduce the mortality rate in the Sarin treated animals. That there were no
significant differences in lethality between DPAT groups suggests that it was without
major effect. The small difference in the mortality rate could be due to inter individual
differences in susceptibility of animals to Sarin treatment. We measured total body
weight loss up to 3 days in all DPAT groups. Only the 1-minute DPAT group had lower
weight loss than toxic challenge at both 1 and 3 days. None of the DPAT group has
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significantly lower weight loss than toxic challenge group. Lower food and water intake
could be the reason of weight loss after Sarin injection after 3 days.
Mice were observed using a Functional Observational Battery for 1-hour post
Sarin dosing. As neurobehavioral assessments during the preliminary stages of chemical
testing are important, it is critical that the screening procedures utilized be valid
indicators of neurobehavioral function and that they be sensitive, specific, and reliable.
In many instances, the effects observed with the FOB may be predictive of
symptomology in humans and comparisons can be made between effects detected with
the FOB and other methods of measuring neurotoxicity. (Moser, 1990;Si, et al., 2007)
We observed higher FOB scores in all Sarin treated groups. There were no significant
differences between any of the Sarin treated groups. We observed a significant
difference in FOB scores between vehicle control and Sarin treated groups. We only
measured 1 hour time point FOB score post injection and observed no difference in
groups, so we concluded that animals do not recover from acute symptoms if they are not
treated with rescue therapy. We decided to monitor FOB scores for 24 hours in 2, 4 and
6-hour DPAT groups. We did not observe any significant difference in FOB score
between toxic challenge and DPAT groups in any time points. It confirms DPAT is not a
rescue drug and it does not have any effects on acute effects produce by neurotoxicity of
sarin dose.
We also measured blood and brain cholinesterase activity 14 days post
injections in groups. Acute symptoms of sarin are produced by irreversible inhibition of
the cholinesterase enzymes. CBDP alone does not produce any effects on total ChE
levels. We have previously determined in our laboratory that toxic challenge doses of
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Sarin significantly reduce blood cholinesterase activity compared to control group
animals 4 days post injections. We observed no significant difference in blood ChE and
AChE in any of the groups 14 days after treatment. However, new red blood cell
production rapidly restores blood AChE levels and the BuChE in plasma is available
from the liver. Frontal cortex ChE activity was lower in DPAT groups than the toxic
challenge group. It is not clear why this occurred as DPAT neither inhibits nor
regenerates AChE (Mason, 2000) Thus, DPAT is not providing neuroprotection by
reducing in acute symptoms, restoring the animal’s general health more rapidly or by
regenerating AChE.

Neuroprotection by 8-OH-DPAT
Sarin exposure leads to neuronal damage, which includes cell degeneration in
specific areas like the hippocampus, the piriform cortex and the thalamus. This damage
might expand with time to include additional brain areas. Soman exposure causes cell
death in mice, in which damaged neurons continue to be present in hippocampal CA1 up
to 90 days post soman exposure. GFAP staining was evident in dentate gyrus of soman
exposed mice, the GFAP staining consistently increased until 15 th days post exposure.
The cascade of events induces long-term effects. Inhalation of sarin vapors induced
impaired memory processes seen at 1-month post exposure with no recovery of function
during the 6 months follow-up period. Similarly, long-term follow-up of victims of the
sarin attacks in Japan demonstrated neurological as well as emotional and cognitive
changes up to 7 years post exposure. (Collombet, et al., 2007;Grauer, et al., 2008) Longterm impaired neurobehavioral functioning effects were also recently reported following
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low-dose inhalation exposure to sarin and cyclosarin during the 1991 Gulf War. An
appropriate treatment might halt the damaging processes and may even allow for
functional recovery. Current treatment therapies include atropine and 2-PAM, which are
rescue therapy for acute toxicity. Current therapy still does not protect from long term
effects. We found neuroprotection in dentate gyrus of hippocampus with 1mg/kg dose of
8-OH-DPAT. The neuroprotection was significant up to 2 hour DPAT injection after
exposure to sarin. The groups were euthanized 14 days post injections it shows that toxic
challenge mice groups are still showing signs of neurodegeneration. The four-hour
DPAT group GFAP cell count is lower than toxic challenge but is not significant that
shows DPAT is not effective post 2 hour as treatment. (Collombet, et al., 2007;Grauer, et
al., 2008) Initiation and early expression of the seizures are cholinergic phenomenon;
anticholinergics readily terminate seizures at this stage and no neuropathology is evident.
However, if not treated, a transition phase occurs during which the neuronal excitation
leads to neuropathology, where Control with anticholinergics becomes ineffective. With
prolonged epileptic form activity the seizure enters a predominantly non-cholinergic
phase, 5-HT-1A may work as a neuroprotectant. Since DPAT is neuroprotective up to 2
hour it can be given to a patient who does not receive timely rescue therapy to prevent
long term effects. (McDonough, Jr. and Shih, 1993) In another study in our laboratory,
we tested the hypothesis that the neuroprotective effects of 8-OH-DPAT against sarininduced neuropathology resulted from alteration of the seizure pattern. Swiss Webster
mice were implanted subcutaneously (sc) with transmitters and cortical electrodes for
telemetry recordings. Recordings of baseline electroencephalography (EEG) were
obtained and mice were then injected with 200 µg/kg (sc) of Sarin and EEG recordings
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were taken for 4 hours unless death resulted. A second group was dosed with 200 µg/kg
of Sarin and 1 min later DPAT (1.0 mg/kg) (sc). All of the sarin dosed mice exhibited
behavioral signs of seizure activity. The recordings substantiated that seizures occurred
and they continued increasing in severity of spikes. There was a significant difference in
the seizure activity of mice dosed with sarin alone compared to the mice with
sarin+DPAT. The EEG of the sarin dosed mice indicated both high frequency and
amplitude seizure patterns. The seizure pattern of the sarin+DPAT dosed mice revealed
seizure patterns with greater intervals between spikes, lower spike amplitudes, and fewer
spike trains. (Table 6) (Figure 20, 21) These studies demonstrate that 8-OH-DPAT
influences the pattern, intensity, and duration of sarin-induced seizures in mice.
(unpublished versions of work done by Belinda Sims)

Figure20: 30 second baseline recording of cortical EEG of control Swiss Webster mouse.
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Figure 21. 30 second seizure recording of cortical EEG. Swiss Webster mouse dosed
with 200µg/kg of Sarin, 3 hrs post injection. Green marker shows 28 second spike train
and the red dotted lines indicate baseline amplitude threshold.

Figure 22. 30 second seizure recording of cortical EEG. Swiss Webster mouse dosed
with 200µg/kg of Sarin and 1.0 mg/kg DPAT (1 min post Sarin), 3 hrs post injection.
Green markers show 3 second spike trains, red dotted lines indicate baseline amplitude
threshold.

Group

Sarin ALONE

Sarin + DPAT

3 hr, Mean
Spike
Train
Duration,
(seconds)
3.7±1.4

3.4±0.3

Total number
of spike
trains

Inter Spike
Train
Mean
(seconds)

Amplitude
3 hrs post
injection
(µV)

785±293

0.26±0.03

0.91± 0.24

185±25

0.43±0.06

0.21 ± 0.08

Table 6. EEG data of Sarin group compared to DPAT group.
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8-OH-DPAT and emotional learning
Sarin exposure causes memory impairment in rodents and humans. We tested the
ability of the 8-OH-DPAT agonist dose of 1mg/kg and 45 minute after toxic challenge for
its ability to reinstate Fear potentiated startle (FPS) response. We have previously
determined in our laboratory that two low doses sarin to mice produces impairment of
acquisition of fear-potentiated startle response. We assumed that our doses Sarin with
CBDP would produce impairment in acquisition of startle response. On the contrary, our
toxic challenge group learned the conditioning. This result negated the ability of the
study to demonstrate the ability of 8-OH-DPAT to reverse learning deficits. The vehicle
control group learned the conditioning but the difference between pre and posttest was
not significant, as we have previously determined. The results show that our dose was on
the breaking point between interference at low doses and noninterference at higher doses.

Conclusion
We were able to utilize CBDP rodents to more accurately model actual human
exposure. CBDP reduced the dose of Sarin which produces 25-50 % mortality in mice.
This model helps to reduce variability produce by single actual dose of Sarin. We also
observed significant neurodegeneration in dentate gyrus of hippocampus in toxic
challenge group. These results are consistent, repeatable and similar to our previous
laboratory experiments. We were able to produce neuroprotection with the 1mg/kg dose
of the 5-HT-1A agonist 8-OH-DPAT. 8-OH-DPAT was able to produce neuroprotection
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up to 2 hours post toxic challenge. DPAT did not produce any effects on mortality rate,
weight loss or ChE activity. 8-OH-DPAT does not produce any effects on cholinesterase
inhibition. Our laboratory observed that 8-OH-DPAT influences the pattern, intensity,
and duration of sarin-induced seizures in a fashion that could account for the observed
neuroprotection in the dentate gyrus of hippocampus. We suggest that the efficacy of 8OH-DPAT treatment lies in its ability to attenuate glutamate release, thereby putting an
end to seizure activity due to NMDA receptor stimulation. (Srkalovic, et al.,
1994;McDonough, Jr. and Shih, 1993) We have also tested other 5-HT-1A agonists in
our laboratory post toxic challenge injections, including buspirone and S-14506. Both
these compounds increased the mortality rate compare to toxic challenge group but did
not have any effects on weight loss and FOB. The mechanism neuroprotection of 8-OHDPAT is still not definitively determined. Further work should be done to identify the
mechanism of DPAT action.

Sarin exposure leads to long-term effects if current rescue

therapy atropine and 2-PAM is not given to stop initial seizure activity. Since DPAT is
effective up to 2 hours after sarin, it may be an effective therapy for neuroprotection from
the long-term effects produced by sarin induced convulsion. Since DPAT does not
protect from acute symptoms, it is not useful as rescue agent. 8-OH-DPAT may be used
as addition to current rescue treatment of atropine and 2-PAM.
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